Eris Lifesciences Q2 FY27 Results: Consolidated Net Profit ₹187 Crore on Total Income of ₹896 Crore
Earnings
Pharmaceuticals
Blacklitt Research4 min read
State Government Photographer, via Wikimedia Commons (CC0). Illustrative image.
Eris Lifesciences (NSE: ERIS) reported consolidated total income of ₹895.57 crore and net profit of ₹187.14 crore for the quarter ended 30 Sep 2026, it said in a filing on 26 Oct 2026. Standalone total income was ₹501.48 crore and standalone net profit ₹129.15 crore.
Key highlights
Consolidated
Including its subsidiaries
Total income: ₹895.57 crore, up 12.6% YoY and 2.3% QoQ
Net profit and EPS: ₹187.14 crore, up 39.2% YoY; basic EPS ₹13.26, up 50.3% YoY
Exceptional item: ₹35.90 crore customer settlement write down in the quarter
Tax credit from scheme: Current tax credit of ₹96 crore and deferred tax charge of ₹31 crore, per the notes
Standalone
The company on its own, without its subsidiaries
Total income: ₹501.48 crore, down 25.6% YoY and up 6.6% QoQ
Net profit and EPS: ₹129.15 crore, down 13.7% YoY; basic EPS ₹9.32, down 15.1% YoY
Tax credit: Tax expense of minus ₹45.64 crore for the quarter
Exceptional item: ₹35.90 crore customer settlement write down in the quarter
Summary
Consolidated ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
895.57
795.22
+12.6%
875.64
+2.3%
Revenue from operations
892.37
792.41
+12.6%
873.25
+2.2%
Other income
3.20
2.81
+13.9%
2.39
+33.9%
187.14
134.47
+39.2%
143.32
+30.6%
Profit before tax
155.91
172.67
-9.7%
179.49
-13.1%
Finance costs
46.42
49.55
-6.3%
46.65
-0.5%
Depreciation
73.42
69.08
+6.3%
72.07
+1.9%
Tax expense
-31.23
38.20
n/a
36.17
n/a
Net profit margin
20.90%
16.91%
+3.99 pp
16.37%
+4.53 pp
EPS, basic (₹)
13.26
8.82
+50.3%
10.28
+29.0%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated net profit rose 39.2% YoY while total income rose 12.6%, and profit before tax fell 9.7%. The gap between the two profit measures sits in tax: the consolidated tax line is a credit of ₹31.23 crore against a charge of ₹38.20 crore a year earlier, so profit after tax moved differently from profit before tax.
The consolidated tax line includes the effect of the Scheme of Arrangement, which the notes put at a current tax credit of ₹96 crore and a deferred tax charge of ₹31 crore for the quarter. Net of those two items the scheme adds ₹65 crore of credit. The notes do not say whether these amounts will recur.
Finance costs of ₹46.42 crore are 5.2% of consolidated total income, down from ₹49.55 crore a year earlier. Other income of ₹3.20 crore is 2.1% of profit before tax. Consolidated EPS of ₹13.26 compares with ₹8.82 a year earlier and ₹10.28 in the previous quarter.
The consolidated figures carry a ₹35.90 crore exceptional item for a settlement with customers over products launched at risk in earlier periods. The notes describe it as a write down of amounts due from those customers, net of collections and past provisions.
Standalone ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
501.48
674.09
-25.6%
470.37
+6.6%
Revenue from operations
482.24
650.50
-25.9%
443.99
+8.6%
Other income
19.24
23.59
-18.4%
26.38
-27.1%
129.15
149.57
-13.7%
48.30
+167.4%
Profit before tax
83.51
234.67
-64.4%
64.14
+30.2%
Finance costs
42.06
46.50
-9.5%
42.16
-0.2%
Depreciation
40.88
39.30
+4.0%
39.98
+2.3%
Tax expense
-45.64
85.10
n/a
15.84
n/a
Net profit margin
25.75%
22.19%
+3.57 pp
10.27%
+15.49 pp
EPS, basic (₹)
9.32
10.98
-15.1%
3.49
+167.0%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone total income fell 25.6% YoY, with revenue from operations down 25.9% and other income down 18.4%.
Standalone net profit is ₹57.99 crore lower than consolidated net profit. Standalone other income of ₹19.24 crore is 23.0% of standalone profit before tax of ₹83.51 crore, a larger share than on a consolidated basis. The reason for the standalone tax credit is not stated in the filing.
Standalone finance costs of ₹42.06 crore are 8.4% of total income. Standalone EPS fell to ₹9.32 from ₹10.98 a year earlier, while the previous quarter was ₹3.49.
The standalone statement carries the same ₹35.90 crore customer settlement exceptional item as the consolidated statement.
Eris Lifesciences operates in one business segment, pharmaceuticals, according to the notes. Consolidated net worth stood at ₹4,141.57 crore at 30 Sep 2026 and standalone net worth at ₹3,288.42 crore. The consolidated interest service coverage ratio is 5.15 times and the standalone ratio 3.84 times.
The Scheme of Arrangement involving Aprica Healthcare Limited, Eris Oaknet Healthcare Private Limited and Eris Therapeutics Limited was approved by the NCLT on 24 Sep 2026 and became effective on 22 Oct 2026, according to the notes. The company also completed the acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for ₹50 crore on 31 Mar 2026, with the purchase price allocation not yet final.
Inference
The filing reports a dividend paid of ₹99.88 crore and consideration paid for a business combination of ₹39.00 crore in the half year ended 30 Sep 2026, and the company allotted 1,95,682 shares under its Employee Stock Option Scheme 2021. The limited review reports on both statements are unmodified.
The filing does not say which dividend the ₹99.88 crore payment relates to, or whether the scheme tax items will recur in later quarters.
Create a free account to read the rest of this article and the analysis that follows.
By continuing you agree to our Terms and Privacy Policy, and to receive updates from Blacklitt by email. You can unsubscribe anytime.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
